Key Highlights
- German pharmaceutical company Merck KGaA announces $11.3 billion acquisition of Bio-Techne, marking its biggest transaction in more than ten years
- The purchase price of $73 per share represents a 24% premium above Bio-Techne’s previous day closing price
- Shares of Bio-Techne stock climbed 20% to reach $70.58 during Thursday’s premarket session
- Transaction completion is anticipated between late 2026 and early 2027
- Merck projects approximately 140 million euros in synergies to be achieved within three years post-closure
Shares of Bio-Techne (TECH) stock experienced a significant 20% rally, reaching $70.58 during premarket hours Thursday following the announcement that Germany’s pharmaceutical leader Merck KGaA has entered into an agreement to purchase the company in an $11.3 billion transaction.
The German pharmaceutical giant is paying $73 for each share, representing a 24% premium compared to where Bio-Techne closed on Wednesday. Merck KGaA’s own shares climbed 3% following the announcement.
This transaction represents the most significant acquisition Merck KGaA has undertaken in more than a decade — its previous deal of similar magnitude was the 2014 acquisition of Sigma-Aldrich.
The purchase also marks the inaugural major transaction under CEO Kai Beckmann’s leadership, who assumed the position in May, succeeding Belén Garijo.
Bio-Techne specializes in providing research reagents, proteins, antibodies, and analytical instruments utilized by scientists and pharmaceutical developers worldwide. The company’s extensive portfolio features 6,000 proteins and an impressive 425,000 antibodies.
During a Thursday morning media briefing, Merck’s Life Science CEO Jean-Charles Wirth described the extensive catalog as a “big, big plus” for the customer base.
Bolstering Life Sciences Capabilities
The strategic acquisition aims to strengthen Merck’s footprint in cutting-edge biological research and the rapidly growing cell and gene therapy sectors.
According to Merck, this transaction solidifies life sciences as the company’s principal growth engine moving forward.
Leerink analyst Puneet Souda noted that Merck seems to be securing a compelling asset with robust long-term growth prospects, even amid current headwinds facing the research tools sector.
Several analysts indicated they don’t anticipate significant regulatory obstacles for the deal’s approval.
Financial Structure and Anticipated Synergies
Merck intends to finance the transaction through a combination of available cash reserves and debt financing. According to its latest quarterly financial report, the company maintained approximately 2.74 billion euros in cash holdings.
The pharmaceutical company anticipates achieving cost synergies totaling roughly 140 million euros, with full realization expected by year three following deal completion.
The transaction is projected to reach closure sometime between late 2026 and early 2027.
This acquisition continues a broader mergers and acquisitions initiative launched under Garijo’s tenure, which encompassed the purchases of Exelead, Mirus Bio, and SpringWorks Therapeutics spanning mRNA manufacturing, cell and gene therapy technologies, and rare disease treatments.
Jean-Charles Wirth stated the deal “strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences.”
